Literature DB >> 22922018

Epitope mapping of botulinum neurotoxins light chains.

Alexey Zdanovsky1, Denis Zdanovsky, Maria Zdanovskaia.   

Abstract

Botulinum neurotoxins (BoNTs) are listed among the most potent biothreat agents. Simultaneously, two out of seven known serotypes of these toxins are used in medicine and cosmetics. This situation calls for development of detailed epitope maps of these toxins. Such maps will help to develop new ways for decreasing damage caused by these toxins if they were to be used as weapons while retaining the therapeutic effect of these toxins used as medicine. Here, we used a library of random fragments of DNA encoding the catalytic domain of botulinum neurotoxin serotype A to identify short epitope-forming sequences. We demonstrated that knowledge of such sequences in a BoNT of one serotype can be used for identification of epitope-forming sequences in other serotypes of BoNTs. We also demonstrated a serodiagnostic value of identified sequences and their ability to retain epitope-specific structures and trigger production of corresponding antibodies, even when they are transferred into a background of a completely alien carrier protein.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22922018      PMCID: PMC3477267          DOI: 10.1016/j.toxicon.2012.08.002

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  45 in total

1.  High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.

Authors:  D D Pless; E R Torres; E K Reinke; S Bavari
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

2.  Epitope mapping of neutralizing botulinum neurotoxin A antibodies by phage display.

Authors:  B P Mullaney; M G Pallavicini; J D Marks
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

3.  Genetic and immunological comparison of anti-botulinum type A antibodies from immune and non-immune human phage libraries.

Authors:  Peter Amersdorfer; Cindy Wong; Theresa Smith; Steven Chen; Sharad Deshpande; Robert Sheridan; James D Marks
Journal:  Vaccine       Date:  2002-02-22       Impact factor: 3.641

Review 4.  Deciphering antibody properties that lead to potent botulinum neurotoxin neutralization.

Authors:  James D Marks
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

5.  Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.

Authors:  A B Scott
Journal:  Ophthalmology       Date:  1980-10       Impact factor: 12.079

6.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

7.  Botulinum A toxin injection as a treatment for blepharospasm.

Authors:  A B Scott; R A Kennedy; H A Stubbs
Journal:  Arch Ophthalmol       Date:  1985-03

8.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

9.  Isolation and characterization of a neutralizing antibody specific to internalization domain of Clostridium botulinum neurotoxin type B.

Authors:  Gi-Hyeok Yang; Kyu-Sik Kim; Hak-Woo Kim; Sung Tae Jeong; Gyung Heng Huh; Ji Cheon Kim; Hyun Ho Jung
Journal:  Toxicon       Date:  2004-07       Impact factor: 3.033

Review 10.  Basic immunological aspects of botulinum toxin therapy.

Authors:  M Zouhair Atassi
Journal:  Mov Disord       Date:  2004-03       Impact factor: 10.338

View more
  1 in total

1.  Development of neutralizing scFv-Fc against botulinum neurotoxin A light chain from a macaque immune library.

Authors:  Sebastian Miethe; Christine Rasetti-Escargueil; Yvonne Liu; Siham Chahboun; Thibaut Pelat; Arnaud Avril; André Frenzel; Thomas Schirrmann; Philippe Thullier; Dorothea Sesardic; Michael Hust
Journal:  MAbs       Date:  2014-01-09       Impact factor: 5.857

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.